Celularity

Celularity Capital Intensity

The Capital Intensity Ratio of Celularity (CELU) as of Oct 16, 2026 is 404.25 %. In the previous year, Capital Intensity Ratio was 244.71 % — a change of 65.20% (higher).

Capital Intensity

404.25 %

YoY

65.20%

Last updated:

Capital Intensity Ratio of Celularity is 2025 404.25 % . Capital Intensity Ratio of Celularity was 2024 244.71 % . It decreases by 65.20% higher compared to the previous year.

The Celularity Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
0.14 USD
Jan 1, 2019
2,466.05 USD
Jan 1, 2020
3,018.69 USD
Jan 1, 2021
1,941.07 USD
Jan 1, 2022
2,231.24 USD
Jan 1, 2023
631.90 USD
Jan 1, 2024
244.71 USD
Jan 1, 2025
404.25 USD
The Celularity Capital Intensity history
YEARCapital IntensityYoY
404.25 %+65.20%
244.71 %-61.27%
631.90 %-71.68%
2,231.24 %+14.95%
1,941.07 %-35.70%
3,018.69 %+22.41%
2,466.05 %+1.75 M%
0.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celularity Stock analysis

What does Celularity do? Celularity Inc, listed on the stock market with ticker CELU and ISIN US1511902041, is a biotechnology company headquartered in Florham Park, New Jersey, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Celularity has 225 employees and completed its initial public offering (IPO) on May 23, 2019. The company focuses on developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune disorders, and infectious diseases. Its research and development efforts include various therapy product candidates such as T cells engineered with a chimeric antigen receptor (CAR), natural killer cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target a range of conditions including cancer, infectious diseases, and degenerative diseases. Celularity's product pipeline features several programs, including CYCART-19, which is a placental-derived CAR-T cell therapy targeting B-cell malignancies, and pEXO-001, among others. The company's operations are structured around three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Celularity's website is https://celularity.com/. Celularity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celularity stock

Capital Intensity Ratio of Celularity is 404.25 % in 2025.

Capital Intensity Ratio of Celularity changed from 244.71 % to 404.25 %, representing a 65.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Celularity since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Celularity with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Celularity

All Key Metrics — Celularity